Casi Pharmaceuticals reports Q1 EPS (69c) vs. (71c) last year

Reports Q1 revenue $6.2M vs. $3.4M last year. Dr. Wei-Wu He, CEO, commented, “We remained focused on advancing the development of our lead program, CID-103. We dosed the initial patient in the third cohort at the target dose of 300mg in our Phase 1/2 dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of CID-103 in adults with chronic immune thrombocytopenia. Simultaneously, we continue to work toward resolving the FDA clinical hold on our renal allograft antibody-mediated rejection program.”